Search

Displaying results 2271 - 2280 of 10000 in total
  1. Drug

    Glycopyrronium

    go.drugbank.com/drugs/DB00986
    ApprovedInvestigationalVet approved

    Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergi...

  2. Drug

    Diazepam

    go.drugbank.com/drugs/DB00829
    ApprovedIllicitInvestigationalVet approved

    Its actions are mediated by enhancement of gamma-aminobutyric acid activity.

  3. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    It boasts the option of single-dose administration and has been proven as non-inferior to a full course of [vancomycin] therapy. … It was developed by The Medicines Company (acquired by Novartis).

  4. Drug

    Amphotericin B

    go.drugbank.com/drugs/DB00681
    ApprovedInvestigational

    While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. … Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by

  5. Drug

    XEN-2174

    go.drugbank.com/drugs/DB05012
    Experimental

    In episodes of pain, inhibition of NET by XEN-2174 elevates the levels of NE leading to the activation of inhibitory pathways preventing pain signals from reaching the brain. … XEN-2174 represents a new class of molecules, called the chi conopeptides that selectively inhibit the Norepinephrine Transporter (NET).

  6. Indication

    Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

    go.drugbank.com/conditions/DBCOND0146855
    Drugs: Pemetrexed
    Synonyms: Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
  7. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    It is available under the brand name Olita made by Hanmi Pharmaceuticals [A19196]. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  8. Drug

    Tralokinumab

    go.drugbank.com/drugs/DB12169
    ApprovedInvestigational

    Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the … It neutralizes IL-13 activity by inhibiting its ability to bind with receptors, thus helping to alleviate AD symptoms.

  9. Drug

    Nisoxetine

    go.drugbank.com/drugs/DB09186
    Experimental

    It was originally investigated as an antidepressant but has no current clinical applications aside from being a research standard SNRI. … It has been used to research obesity and energy balance, and exerts some local analgesia effects.

  10. Drug

    MLN0415

    go.drugbank.com/drugs/DB05183
    Experimental

    MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. … In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins.